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[11] John R, Pagani FD, Naka Y, Boyle A, Conte JV, Russell SD et al. There are many drugs from oxygen and NO, and so on. My third question is, could you tell us something about the morbidity of the patients who were on the LVAD before transplantation?
Dr Kutty: In regard to the first question, as you very correctly mentioned, there is variation in the definition of pulmonary hypertension in these patients, and it varies from institution to institution and governing body. The ISHLT have suggested criteria, but they are not defined or formalized. Our protocol mirrors their suggestions but this protocol is specific to our unit. That is our definition of secondary pulmonary hypertension before we would consider LVAD implantation.
Concerning your second question on medication, I have read your excellent expert review and very elegantly written article about the Freiburg protocol. We do not have a specific protocol that we use at Papworth Hospital. However, our transplant physicians and our surgeons work closely together in decision-making and treatment. We would consider oxygen. We do not use dobutamine in our unit to identify fixed pulmonary hypertension. We do use phosphodiesterase inhibitors such as sildenafil prior to patients coming into the hospital to see if there is any benefit. A lot of our patients have preoptimization prior to the LVAD implant which involves dopamine infusions, an intra-aortic balloon pump and aggressive diuresis prior to LVAD implantation.
Thirdly, regarding comorbidity, the biggest morbidities we have seen would be driveline infections and requirement for transfusion. However, with the newer devices, especially with the hardware where you tunnel the line, we have had a lot less in the way of driveline infections. Regarding transfusion requirements, we have quite strict criteria for transfusing these patients after LVAD implantation due to the fact that a major problem is that they may become sensitized and poor candidates for transplantation because of repeated transfusions. It is primarily down to meticulous surgical technique and hemostasis at the time of procedure, and limitation of blood product transfusion in the postoperative phase. 
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In patients with advanced heart failure, elevated pulmonary vascular resistance as a consequence of a chronic elevation in left atrial pressure is a significant risk for early mortality after heart transplantation [1] . Heart failure patients with elevated pulmonary vascular resistance can be extremely challenging to manage, and medical options to reduce pulmonary vascular resistance so that the patient becomes an acceptable transplant candidate are limited. In some, intensive therapies including inotropes may be of benefit, though even if successful, they will need to stay on these therapies until the time that a suitable donor heart can be found. Heart lung transplantation and heterotopic heart transplantation are alternative transplant options that are now rarely performed. Ventricular assist devices, however, can reduce pulmonary vascular resistance effectively after a period of support so that the patient then becomes an acceptable transplant candidate [2, 3] . In the current issue, Kutty et al. [4] show how third-generation centrifugal left ventricular assist devices can reduce pulmonary vascular resistance in a group of patients who were implanted with the ultimate aim of transplantation. As they state in the article, with pulsatile and axial flow devices, reduction in pulmonary vascular resistance has been documented [2, 3] , and the new information in this paper shows the same effect with thirdgeneration devices. In this paper, 29 patients had centrifugal left ventricular assist devices implanted, of which 17 were ineligible for transplantation because of elevated pulmonary vascular resistance. Pulmonary vascular resistance fell from 5 ± 1.5 to 2.1 ± 0.5 Wood units (P < 0.05), and by 3 months of support, the average pulmonary vascular resistance was well within the transplantable range. The authors acknowledge that, as a singlecentre study, the numbers are small in this study, though it is with these types of studies that we learn a greater amount of detail than with large multicentre studies. That said, the authors have missed the opportunity to provide additional information about these patients that would be very useful to clinicians who use these devices. Data on left and right ventricular function with echocardiography would be extremely informative, as would medications used after the ventricular assist device implant. In particular, we are not told whether phosphodiesterase Type 5 inhibitors were used. Nevertheless, the data are clear: pulmonary vascular resistance reduces with third-generation centrifugal left ventricular assist devices so that these patients can then become transplant candidates. These data now add to an increasing number of publications demonstrating the clinical efficacy of these newer devices [5, 6] .
It is with some degree of irony that, despite this paper originating from the Papworth Hospital in the UK, the UK Department of Health has recently decided that a left ventricular assist device can only be implanted in patients who are already on the transplant list. This means that the very patients who are the subject of the current paper would today be considered ineligible for a left ventricular assist device because of elevated pulmonary vascular resistance-even though, the evidence shows that, after a period of time, they will become transplant candidates. Economies throughout the world are struggling, with the consequence that health budgets are being squeezed. Nevertheless, it is still reasonable to expect that where cuts in medical services are to be enforced, they should be for therapies without proven benefit, as opposed to any arbitrary decision.
Furthermore, rather than restricting access to life-saving therapies, there is a need for greater access to left ventricular assist devices for advanced heart failure. Heart transplant numbers are inadequate for the number of heart failure patients and will always be so [7] . Randomized-controlled trials have shown the benefits of ventricular assist devices as destination therapy [8] , and this is now recommended in the European Society of Cardiology guidelines [9] . Data about ventricular assist devices throughout the world are difficult to find. Whereas, in the USA, there are large numbers of ventricular assist devices implanted as destination therapy, in many other developed countries, this is still not sanctioned. Cost is a limiting factor, but other factors are also important-the lack of patient awareness and the lack of physician awareness and/or expertize in managing these patients. With respect to cost, the real issue is cost effectiveness, and cost effectiveness studies, to date, have been flawed, with inappropriate assumptions and comparison groups [10] . Furthermore, it is very difficult to translate costs from one health system to another. Properly designed, cost effectiveness studies are necessary. The lack of patient and physician awareness is a problem that seems particular to heart failure. It is hard to imagine cancer sufferers and their doctors being so reticent about a life-saving treatment. Perhaps, the onus is on those who treat advanced heart failure to ensure that our patients and referring physicians understand that there are options for these patients utilizing ventricular assist devices-with or without transplantation.
